Retrospective Study of Nearly 100,000 Patients Shows Neurolens® with Contoured Prism™ Technology Delivers Statistically Significant Symptom Improvement Compared to Conventional Prism.

Newton™, Inc. (formerly Neurolens®), a leader in innovative eye care technology, today announced findings from a groundbreaking retroactive study of 96,745 patient records that demonstrates Neurolens with Contoured Prism technology delivers greater symptom relief than conventional prism.

Key findings: Compared to conventional prism, Neurolens with Contoured Prism delivers:

  • 41% greater improvement in headaches
  • 53% greater improvement in neck and shoulder stiffness
  • 27% greater improvement in tired eyes symptom scores
  • 28% greater improvement in overall symptom scores

“This is the largest real-world dataset examining prism-based treatments for binocular vision anomalies to date,” said Dr. Singh, Director of Clinical Affairs at Newton. “The results provide compelling evidence that Neurolens with Contoured Prism offers enhanced therapeutic benefit beyond conventional prism correction.”

You can access the full whitepaper here: https://neurolens.com/

Clinical Decision-Making and Patient Selection

Based on the study findings, clinicians may consider Neurolens as a first-line treatment option for patients presenting with:

  • Persistent headaches associated with near work or digital device use
  • Neck and shoulder tension that worsens throughout the day
  • Visual fatigue and tired eyes, particularly toward end of day

What Makes Contoured Prism Technology Different

Unlike conventional prism, which provides uniform correction across the entire lens surface, Neurolens features patented Contoured Prism technology that varies the amount of prism correction from distance to near viewing, matching the eyes’ natural alignment needs throughout the day. This dynamic application of prism is why Neurolens with Contoured Prism technology is the only lens solution proven to relieve the painful symptoms of eye misalignment, such as headaches, neck pain, and motion sickness.

In a 2024 peer-reviewed, randomized, controlled, double-masked, cross-over trial published in Translational Vision Science & Technology, Neurolens demonstrated a life-changing level of impact using the widely accepted and validated Headache Impact Test, or HIT-6 questionnaire. Neurolens has also been shown to significantly reduce “prism creep” – the tendency for patients to require increasing amounts of prism correction at subsequent visits to maintain visual comfort benefit.1

About the Study

The study, authored by Newton Director of Clinical Affairs Dr. Sumeer Singh, found that Neurolens with Contoured Prism technology provides patients with statistically significant symptom improvement compared to those wearing conventional prism (p<0.01). The retrospective analysis utilized clinical data from 96,745 patients at Neurolens provider locations collected between September 2023 and October 2025. Statistical analysis confirmed that all improvements in the Neurolens group were statistically significant (p < 0.01) compared to both conventional prism and control groups.

About Newton

Newton is an innovation company transforming eye care through exceptional patient experiences and outcomes. With patented Contoured Prism technology in the Neurolens portfolio and breakthrough Convergence Boost™ technology in Sequel™ lenses, Newton empowers eye care providers to deliver measurable relief while elevating the standard of care industry wide.

For more information, visit www.newton.tech.

Media Contact

Chase Cutler | Sr. Director of Marketing | chase.cutler@newton.tech

References

    1. Data on file. Newton.